fluoxetine has been researched along with Chemical Dependence in 62 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluoxetine combined with CBT had greater efficacy than did placebo and CBT according to changes on the Childhood Depression Rating Scale-Revised (effect size, 0." | 9.12 | A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. ( Davies, RD; Klein, C; Lohman, M; Mikulich-Gilbertson, SK; Riggs, PD; Stover, SK, 2007) |
| " The adverse event profile in obese patients, though differing slightly from that seen in depressed patients, was similar in that events observed were generally mild and well tolerated." | 5.27 | Safety of fluoxetine in the treatment of obesity. ( Zerbe, RL, 1987) |
| " Participants were diagnosed with depressive disorders and randomly assigned to receive directly observed therapy with fluoxetine or a referral to community mental health treatment." | 5.24 | Does substance use compromise depression treatment in persons with HIV? Findings from a randomized controlled trial. ( Bangsberg, DR; Dilley, JW; Grelotti, DJ; Hammer, GP; Karasic, DH; Sorensen, JL; Tsai, AC, 2017) |
| "Fluoxetine combined with CBT had greater efficacy than did placebo and CBT according to changes on the Childhood Depression Rating Scale-Revised (effect size, 0." | 5.12 | A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. ( Davies, RD; Klein, C; Lohman, M; Mikulich-Gilbertson, SK; Riggs, PD; Stover, SK, 2007) |
| "Stabilised MMPs scoring over 21 on the Beck Depression Inventory were randomised to receive fluoxetine or placebo over 12 weeks." | 5.10 | A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms. ( Bell, J; Christie, MJ; Dean, AJ; Mascord, DJ; Parker, G, 2002) |
| "Although fluoxetine might be more effective than placebo for treating adolescent depression without major comorbidity, little is known about the response of depressive symptoms to antidepressants in adolescents with comorbid conduct disorder (CD) and substance use disorders (SUD)." | 5.08 | Fluoxetine in drug-dependent delinquents with major depression: an open trial. ( Coffman, LM; Crowley, TJ; Mikulich, SK; Riggs, PD, 1997) |
| " In this study, 17 patients with DSM-III-R diagnoses of major depressive disorder, alcohol dependence, and cocaine abuse were included along with 34 non-cocaine-abusing depressed alcoholics in a pharmacotherapy trial involving the SSRI antidepressant fluoxetine." | 5.08 | Fluoxetine versus placebo in depressed alcoholic cocaine abusers. ( Cornelius, JR; Daley, DC; Haskett, RF; Jones-Barlock, A; Perel, JM; Salloum, IM; Thase, ME; Upsher, C, 1998) |
| "Transdermal fentanyl is an opioid analgesic that is effective on chronic pain, and which appears to be advantageous due to several factors such as ease of administration, the relatively stable serum concentration and long dose intervals." | 3.72 | Oral transmucosal abuse of transdermal fentanyl. ( Dimopoulos, NP; Gitsa, OE; Liappas, AI; Liappas, IA; Mellos, E; Rabavilas, AD, 2004) |
| "We report nine cases where fluoxetine (FX) (20 mg/day) was added to maintenance treatment with methadone (MTD) (dose range: 30-100 mg) in addicts with affective disorders." | 3.69 | Fluoxetine addition to methadone in addicts: pharmacokinetic aspects. ( Baumann, P; Bertschy, G; Eap, CB; Powell, K, 1996) |
| "Fluoxetine was well tolerated in combination with methadone and did not appear to alter methadone concentrations in plasma." | 2.67 | Fluoxetine for cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine/benzoylecgonine concentrations. ( Batki, SL; Jacob, P; Jones, RT; Manfredi, LB, 1993) |
| "Informing drug abusers in treatment regarding positive HIV-serostatus was not associated with a lower treatment-retention rate or adverse psychological reactions when counseling regarding HIV issues was integrated with drug abuse treatment." | 2.67 | Psychological reactions and retention by cocaine addicts during treatment according to HIV-serostatus: a matched-control study. ( Brown, BS; Haertzen, CA; Hess, JM; Weddington, WW, 1991) |
| " The adverse reactions include the "serotonin syndrome", cardiovascular complications, extrapyramidal side effects such as akathisia, dyskinesias, and parkinsonian-like syndromes and an apparently increased risk of suicidality." | 2.38 | Fluoxetine: adverse effects and drug-drug interactions. ( Messiha, FS, 1993) |
| "Zolpidem is an imidazopyridine hypnotic that is believed to act selectively at alpha(1) subunit-containing gamma-aminobutyric acid type A (GABA(A)) receptors and thus to have minimal abuse and dependence potential." | 1.32 | Three cases of zolpidem dependence treated with fluoxetine: the serotonin hypothesis. ( Christodoulou, GN; Dimopoulos, NP; Gitsa, OE; Liappas, AI; Liappas, IA; Malitas, PN; Nikolaou, CK, 2003) |
| "Because of a depressive syndrome, a 39-year-old patient received 20 mg fluoxetine per day." | 1.29 | [A case of rare side effects of certain antidepressive drugs]. ( Haenel, T; Stöckli, HR; Truog, P, 1995) |
| "Fluoxetine pretreatment, likewise, reduced responding in non-lesioned rats and had no observable effect in lesioned animals." | 1.27 | The effects of putative 5-hydroxytryptamine receptor active agents on D-amphetamine self-administration in controls and rats with 5,7-dihydroxytryptamine median forebrain bundle lesions. ( Leccese, AP; Lyness, WH, 1984) |
| " The adverse event profile in obese patients, though differing slightly from that seen in depressed patients, was similar in that events observed were generally mild and well tolerated." | 1.27 | Safety of fluoxetine in the treatment of obesity. ( Zerbe, RL, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (6.45) | 18.7374 |
| 1990's | 35 (56.45) | 18.2507 |
| 2000's | 15 (24.19) | 29.6817 |
| 2010's | 7 (11.29) | 24.3611 |
| 2020's | 1 (1.61) | 2.80 |
| Authors | Studies |
|---|---|
| Ikram, H | 1 |
| Tasneem, S | 1 |
| Perveen, S | 1 |
| Zakir, R | 1 |
| Jabeen Haleem, D | 1 |
| Connor, DA | 1 |
| Gould, TJ | 1 |
| Jain, S | 1 |
| Gupta, T | 1 |
| Nebhinani, N | 1 |
| Singhai, K | 1 |
| Suthar, N | 1 |
| Hinckley, JD | 1 |
| Riggs, P | 1 |
| Dierksen, J | 1 |
| Gonsoulin, M | 1 |
| Walterscheid, JP | 1 |
| Grelotti, DJ | 1 |
| Hammer, GP | 1 |
| Dilley, JW | 1 |
| Karasic, DH | 1 |
| Sorensen, JL | 2 |
| Bangsberg, DR | 1 |
| Tsai, AC | 1 |
| Gao, K | 1 |
| Kemp, DE | 1 |
| Ganocy, SJ | 1 |
| Muzina, DJ | 1 |
| Xia, G | 1 |
| Findling, RL | 2 |
| Calabrese, JR | 1 |
| Ayala, ME | 1 |
| Hirschtritt, ME | 1 |
| Pagano, ME | 1 |
| Christian, KM | 1 |
| McNamara, NK | 1 |
| Stansbrey, RJ | 1 |
| Lingler, J | 1 |
| Faber, JE | 1 |
| Demeter, CA | 1 |
| Bedoya, D | 1 |
| Curry, J | 1 |
| Silva, S | 1 |
| Rohde, P | 1 |
| Ginsburg, G | 1 |
| Kennard, B | 1 |
| Kratochvil, C | 1 |
| Simons, A | 1 |
| Kirchner, J | 1 |
| May, D | 1 |
| Mayes, T | 1 |
| Feeny, N | 1 |
| Albano, AM | 1 |
| Lavanier, S | 1 |
| Reinecke, M | 1 |
| Jacobs, R | 1 |
| Becker-Weidman, E | 1 |
| Weller, E | 1 |
| Emslie, G | 1 |
| Walkup, J | 1 |
| Kastelic, E | 1 |
| Burns, B | 1 |
| Wells, K | 1 |
| March, J | 1 |
| Dean, AJ | 1 |
| Bell, J | 1 |
| Mascord, DJ | 1 |
| Parker, G | 1 |
| Christie, MJ | 1 |
| Liappas, IA | 2 |
| Malitas, PN | 1 |
| Dimopoulos, NP | 2 |
| Gitsa, OE | 2 |
| Liappas, AI | 2 |
| Nikolaou, CK | 1 |
| Christodoulou, GN | 1 |
| Seymour, PM | 1 |
| Mellos, E | 1 |
| Rabavilas, AD | 1 |
| Giroud, C | 1 |
| Michaud, K | 1 |
| Sporkert, F | 1 |
| Eap, C | 1 |
| Augsburger, M | 1 |
| Cardinal, P | 1 |
| Mangin, P | 1 |
| Cornelius, JR | 3 |
| Clark, DB | 2 |
| Bukstein, OG | 1 |
| Birmaher, B | 1 |
| Salloum, IM | 3 |
| Brown, SA | 1 |
| Stemmelin, J | 1 |
| Cohen, C | 1 |
| Terranova, JP | 1 |
| Lopez-Grancha, M | 1 |
| Pichat, P | 1 |
| Bergis, O | 1 |
| Decobert, M | 1 |
| Santucci, V | 1 |
| Françon, D | 1 |
| Alonso, R | 1 |
| Stahl, SM | 1 |
| Keane, P | 1 |
| Avenet, P | 1 |
| Scatton, B | 1 |
| le Fur, G | 1 |
| Griebel, G | 1 |
| Greenwald, MK | 1 |
| Arnold, KK | 1 |
| Yager, J | 1 |
| Riggs, PD | 2 |
| Mikulich-Gilbertson, SK | 1 |
| Davies, RD | 1 |
| Lohman, M | 1 |
| Klein, C | 1 |
| Stover, SK | 1 |
| Leccese, AP | 1 |
| Lyness, WH | 2 |
| Covi, L | 1 |
| Hess, JM | 2 |
| Kreiter, NA | 1 |
| Haertzen, CA | 2 |
| Polles, AG | 1 |
| Smith, PO | 1 |
| Petrakis, I | 1 |
| Carroll, K | 1 |
| Gordon, L | 1 |
| Cushing, G | 1 |
| Rounsaville, B | 1 |
| Balon, R | 1 |
| Walsh, SL | 1 |
| Preston, KL | 1 |
| Sullivan, JT | 1 |
| Fromme, R | 1 |
| Bigelow, GE | 1 |
| Haenel, T | 1 |
| Stöckli, HR | 1 |
| Truog, P | 1 |
| Tinsley, JA | 1 |
| Olsen, MW | 1 |
| Laroche, RR | 1 |
| Palmen, MA | 1 |
| McCann, UD | 1 |
| Ricaurte, GA | 1 |
| Freeman, H | 1 |
| Kaplan, R | 1 |
| Walder, J | 1 |
| Messiha, FS | 1 |
| Batki, SL | 2 |
| Manfredi, LB | 2 |
| Jacob, P | 2 |
| Jones, RT | 2 |
| Barrett, J | 1 |
| Meehan, O | 1 |
| Fahy, T | 1 |
| Bertschy, G | 2 |
| Eap, CB | 2 |
| Powell, K | 2 |
| Baumann, P | 2 |
| Castañeda, R | 1 |
| Levy, R | 1 |
| Westreich, LM | 1 |
| Sussman, N | 1 |
| Belej, T | 1 |
| Manji, D | 1 |
| Sioutis, S | 1 |
| Barros, HM | 1 |
| Nobrega, JN | 1 |
| Gross, R | 1 |
| Higgins, ST | 1 |
| Budney, AJ | 1 |
| Ivanusa, Z | 1 |
| Hećimović, H | 1 |
| Demarin, V | 1 |
| Mikulich, SK | 1 |
| Coffman, LM | 1 |
| Crowley, TJ | 1 |
| Thase, ME | 1 |
| Haskett, RF | 1 |
| Daley, DC | 1 |
| Jones-Barlock, A | 1 |
| Upsher, C | 1 |
| Perel, JM | 1 |
| Behnke, K | 1 |
| Wilkinson, D | 1 |
| Lynch, K | 1 |
| Mann, JJ | 1 |
| Rodgers, TA | 1 |
| Fernandes, LC | 1 |
| Kilicarslan, T | 1 |
| Kaplan, HL | 1 |
| Tyndale, RF | 1 |
| Sellers, EM | 1 |
| Romach, MK | 1 |
| Brooke, D | 1 |
| Fudala, PJ | 1 |
| Johnson, RE | 1 |
| Malone, DA | 1 |
| Dimeff, RJ | 1 |
| Picker, W | 1 |
| Lerman, A | 1 |
| Hajal, F | 1 |
| Nelson, JC | 1 |
| Dumontet, R | 1 |
| Weddington, WW | 1 |
| Brown, BS | 1 |
| Jerome, L | 1 |
| Pollack, MH | 1 |
| Rosenbaum, JF | 1 |
| Bulik, CM | 1 |
| Epstein, LH | 1 |
| Kaye, W | 1 |
| Goldman, MJ | 1 |
| Grinspoon, L | 1 |
| Hunter-Jones, S | 1 |
| Yu, DS | 1 |
| Smith, FL | 1 |
| Smith, DG | 1 |
| Wilcox, JA | 1 |
| Zerbe, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Depression Treatment to Improve Antiretroviral Adherence[NCT00338767] | Phase 2 | 150 participants (Actual) | Interventional | 2001-01-31 | Completed | ||
| Substance Dependent Teens - Impact of Treating Depression Study 1[NCT00061113] | Phase 4 | 126 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for fluoxetine and Chemical Dependence
| Article | Year |
|---|---|
Integrated Treatment of Adolescents with Co-occurring Depression and Substance Use Disorder.
Topics: Adolescent; Cognitive Behavioral Therapy; Delivery of Health Care, Integrated; Depression; Fluoxetin | 2019 |
Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review.
Topics: Adolescent; Alcohol Drinking; Alcoholism; Antidepressive Agents, Second-Generation; Combined Modalit | 2005 |
Fluoxetine: adverse effects and drug-drug interactions.
Topics: Drug Interactions; Extrapyramidal Tracts; Fluoxetine; Heart; Humans; Mental Disorders; Substance-Rel | 1993 |
From the initial clinic contact to aftercare: a brief review of effective strategies for retaining cocaine abusers in treatment.
Topics: Antidepressive Agents; Appointments and Schedules; Clinical Trials as Topic; Cocaine; Desipramine; F | 1997 |
Serotonin syndrome.
Topics: Fluoxetine; Humans; Monoamine Oxidase Inhibitors; Nervous System Diseases; Receptors, Serotonin; Ser | 1997 |
16 trials available for fluoxetine and Chemical Dependence
| Article | Year |
|---|---|
Does substance use compromise depression treatment in persons with HIV? Findings from a randomized controlled trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Female; Fluoxetine; HIV Infections; Humans; Ill-H | 2017 |
Moderators of fluoxetine treatment response for children and adolescents with comorbid depression and substance use disorders.
Topics: Adolescent; Alcoholism; Antidepressive Agents, Second-Generation; Child; Chronic Disease; Depressive | 2012 |
Onset of alcohol or substance use disorders following treatment for adolescent depression.
Topics: Adolescent; Antidepressive Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressi | 2012 |
A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms.
Topics: Adult; Antidepressive Agents; Comorbidity; Depression; Female; Fluoxetine; Humans; Male; Methadone; | 2002 |
A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders.
Topics: Adolescent; Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Depression; | 2007 |
Effects of combined fluoxetine and counseling in the outpatient treatment of cocaine abusers.
Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Cocaine; Combined Modality Therapy | 1995 |
Fluoxetine alters the effects of intravenous cocaine in humans.
Topics: Adult; Affect; Arousal; Blood Pressure; Cocaine; Dose-Response Relationship, Drug; Double-Blind Meth | 1994 |
Fluoxetine for cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine/benzoylecgonine concentrations.
Topics: Adult; Cocaine; Female; Fluoxetine; Humans; Male; Methadone; Middle Aged; Prospective Studies; Psych | 1993 |
Fluoxetine in drug-dependent delinquents with major depression: an open trial.
Topics: Adolescent; Antidepressive Agents; Cannabis; Conduct Disorder; Depressive Disorder; Ethanol; Fluoxet | 1997 |
Fluoxetine versus placebo in depressed alcoholic cocaine abusers.
Topics: Adult; Alcoholism; Antidepressive Agents, Second-Generation; Cocaine; Depressive Disorder; Double-Bl | 1998 |
Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone.
Topics: Fluoxetine; Fluvoxamine; Humans; Methadone; Narcotics; Selective Serotonin Reuptake Inhibitors; Stat | 1997 |
Treating the substance-abusing suicidal patient.
Topics: Adult; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Follow-Up Studies; Humans; Male | 2001 |
Treatment of codeine dependence with inhibitors of cytochrome P450 2D6.
Topics: Adult; Aged; Analgesics, Opioid; Codeine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitor | 2002 |
Weighing up the pros and cons: help-seeking by drug misusers in Baltimore, USA.
Topics: Adult; Bromocriptine; Buprenorphine; Cocaine; Desipramine; Fear; Female; Fluoxetine; Humans; Male; M | 1992 |
Psychological reactions and retention by cocaine addicts during treatment according to HIV-serostatus: a matched-control study.
Topics: Adaptation, Psychological; Adult; Affect; AIDS Serodiagnosis; Amantadine; Baltimore; Cocaine; Combin | 1991 |
Treatment of laxative abuse in a female with bulimia nervosa using an operant extinction paradigm.
Topics: Adult; Behavior Therapy; Bulimia; Cathartics; Cognitive Behavioral Therapy; Combined Modality Therap | 1990 |
41 other studies available for fluoxetine and Chemical Dependence
| Article | Year |
|---|---|
Neurochemical and behavioral effects of fluoxetine on midazolam induce dependence in an animal model of addiction.
Topics: Animals; Behavior, Animal; Drug Interactions; Fluoxetine; Hypnotics and Sedatives; Male; Midazolam; | 2021 |
Chronic fluoxetine ameliorates adolescent chronic nicotine exposure-induced long-term adult deficits in trace conditioning.
Topics: Aging; Animals; Anxiety; Brain-Derived Neurotrophic Factor; Conditioning, Psychological; Fear; Fluox | 2017 |
Therapeutic challenges in comorbid obsessive compulsive disorder with substance use.
Topics: Adrenergic alpha-2 Receptor Agonists; Clonazepam; Clonidine; Combined Modality Therapy; Fluoxetine; | 2018 |
Poor Man's Methadone: A Case Report of Loperamide Toxicity.
Topics: Alprazolam; Antidiarrheals; Chromatography, Liquid; Fluoxetine; Humans; Hypertrophy; Loperamide; Mal | 2015 |
Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder.
Topics: Adult; Affect; Anticonvulsants; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar | 2008 |
Brain serotonin, psychoactive drugs, and effects on reproduction.
Topics: Affect; Amphetamine-Related Disorders; Animals; Biological Clocks; Brain; Cognition Disorders; Depre | 2009 |
Three cases of zolpidem dependence treated with fluoxetine: the serotonin hypothesis.
Topics: Adult; Female; Fluoxetine; GABA Agonists; gamma-Aminobutyric Acid; Humans; Male; Pyridines; Selectiv | 2003 |
Long-term treatment of an addictive personality.
Topics: Adult; Antidepressive Agents, Second-Generation; Behavior, Addictive; Depressive Disorder; Diagnosis | 2003 |
Oral transmucosal abuse of transdermal fentanyl.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Chronic Disease; Depressive Disorder; Drug A | 2004 |
A fatal overdose of cocaine associated with coingestion of marijuana, buprenorphine, and fluoxetine. Body fluid and tissue distribution of cocaine and its metabolites determined by hydrophilic interaction chromatography-mass spectrometry(HILIC-MS).
Topics: Analgesics, Opioid; Biotransformation; Buprenorphine; Cannabinoids; Chromatography, Liquid; Cocaine; | 2004 |
Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.
Topics: Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Aggression; Animals; Anti-Anxiety Age | 2008 |
Behavioral economic analysis of drug preference using multiple choice procedure data.
Topics: Choice Behavior; Economics; Fentanyl; Fluoxetine; Hallucinogens; Humans; Hydromorphone; Injections, | 2008 |
A case of unexpected and selective remission of a 20-year history of ephedrine dependence following treatment with low-dose aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Administration Schedule; | 2007 |
The effects of putative 5-hydroxytryptamine receptor active agents on D-amphetamine self-administration in controls and rats with 5,7-dihydroxytryptamine median forebrain bundle lesions.
Topics: 5,7-Dihydroxytryptamine; Animals; Cyproheptadine; Dextroamphetamine; Fluoxetine; Humans; Male; Media | 1984 |
Treatment of coexisting substance dependence and posttramatic stress disorder.
Topics: Adult; Alcoholism; Behavior Therapy; Combined Modality Therapy; Comorbidity; Fluoxetine; Humans; Ill | 1995 |
Fluoxetine treatment for dually diagnosed methadone maintained opioid addicts: a pilot study.
Topics: Adult; Cocaine; Combined Modality Therapy; Comorbidity; Depressive Disorder; Diagnosis, Dual (Psychi | 1994 |
Fluoxetine for cocaine dependence in methadone maintenance.
Topics: Alcoholism; Cocaine; Dopamine Uptake Inhibitors; Drug Synergism; Fluoxetine; Heroin Dependence; Huma | 1994 |
[A case of rare side effects of certain antidepressive drugs].
Topics: Adult; Antidepressive Agents; Clomipramine; Depressive Disorder; Diagnosis, Differential; Drug Thera | 1995 |
Fluoxetine abuse.
Topics: Adult; Female; Fluoxetine; Humans; Male; Substance-Related Disorders | 1994 |
Reinforcing subjective effects of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidence.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Arousal; Designer Drugs; Dose-Response Relationship, Drug; Dru | 1993 |
Listening to Prozac.
Topics: Fluoxetine; Humans; Substance-Related Disorders | 1994 |
Listening to Prozac.
Topics: Fluoxetine; Humans; Substance-Related Disorders | 1994 |
Listening to Prozac.
Topics: Fluoxetine; Humans; Substance-Related Disorders | 1994 |
SSRI and sympathominetic interaction.
Topics: Adult; Amphetamine; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Flu | 1996 |
Fluoxetine addition to methadone in addicts: pharmacokinetic aspects.
Topics: Adult; Analgesics, Opioid; Antidepressive Agents, Second-Generation; Drug Interactions; Female; Fluo | 1996 |
Drug craving and other negative reactions after abrupt substitution of nefazodone for other serotonergic agents.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Drug Administration Schedule; Female; Fluox | 1996 |
Changes in serotonin and norepinephrine uptake sites after chronic cocaine: pre- vs. post-withdrawal effects.
Topics: Administration, Oral; Animals; Autoradiography; Biological Transport; Brain; Carrier Proteins; Cocai | 1996 |
Fluoxetine abuse.
Topics: Antidepressive Agents, Second-Generation; Fluoxetine; Humans; Substance-Related Disorders | 1996 |
[For some it is a matter of necessity. Worry about the overuse of an antidepressant].
Topics: Depression; Dose-Response Relationship, Drug; Fluoxetine; Humans; Selective Serotonin Reuptake Inhib | 1998 |
Loss of anxiety and increased aggression in a 15-year-old boy taking fluoxetine.
Topics: Adolescent; Aggression; Antidepressive Agents, Second-Generation; Anxiety; Fluoxetine; Humans; Male; | 1999 |
Ethics, humility, and psychotropic medications.
Topics: Adult; Attitude of Health Personnel; Dose-Response Relationship, Drug; Ethics, Medical; Female; Fluo | 2001 |
The use of fluoxetine in depression associated with anabolic steroid withdrawal: a case series.
Topics: Adult; Anabolic Agents; Depressive Disorder; Fluoxetine; Humans; Male; Substance Withdrawal Syndrome | 1992 |
Potential interaction of LSD and fluoxetine.
Topics: Adolescent; Drug Interactions; Epilepsy, Tonic-Clonic; Fluoxetine; Humans; Lysergic Acid Diethylamid | 1992 |
Current status of tricyclic antidepressants in psychiatry: their pharmacology and clinical applications.
Topics: Aged; Antidepressive Agents, Tricyclic; Anxiety Disorders; Cocaine; Depressive Disorder; Feeding and | 1991 |
Fluoxetine for cocaine abuse in methadone patients: preliminary findings.
Topics: Adult; Cocaine; Female; Fluoxetine; Heroin Dependence; Humans; Male; Methadone; Substance-Related Di | 1990 |
Hypomania with fluoxetine.
Topics: Adjustment Disorders; Bipolar Disorder; Child; Fluoxetine; Humans; Male; Substance-Related Disorders | 1991 |
Fluoxetine treatment of cocaine abuse in heroin addicts.
Topics: Adult; Cocaine; Female; Fluoxetine; Follow-Up Studies; Heroin Dependence; Humans; Male; Methadone; S | 1991 |
Ritualistic use of fluoxetine by a former substance abuser.
Topics: Adult; Depressive Disorder; Female; Fluoxetine; Humans; Self Administration; Substance-Related Disor | 1990 |
Fluoxetine-induced attenuation of amphetamine self-administration in rats.
Topics: Amphetamines; Animals; Brain Chemistry; Fluoxetine; Male; Neurons; Propylamines; Rats; Rats, Inbred | 1986 |
Abuse of fluoxetine by a patient with anorexia nervosa.
Topics: Adult; Anorexia Nervosa; Body Weight; Depressive Disorder; Female; Fluoxetine; Humans; Propylamines; | 1987 |
Safety of fluoxetine in the treatment of obesity.
Topics: Drug Interactions; Fluoxetine; Heart; Humans; Lipidoses; Liver; Obesity; Phospholipids; Propylamines | 1987 |